Stockreport

Acorda Receives Refusal to File Letter from FDA for INBRIJA™ (CVT-301, levodopa inhalation powder) New Drug Application

Acorda Therapeutics, Inc.  (ACOR) 
Last acorda therapeutics, inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
PDF ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.S. Foo [Read more]